Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. - Wikidata - awgldk - TriplyDB

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

http://www.wikidata.org/entity/Q37242280

about

Thrombotic microangiopathy with targeted cancer agents Cancer-associated thrombotic microangiopathy Current and emerging treatment options for hairy cell leukemia Toxin-based therapeutic approaches Monoclonal antibodies in acute lymphoblastic leukemia Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial Immunotherapy of childhood cancer: from biologic understanding to clinical application.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Update on the biology and treatment options for hairy cell leukemia.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Engineering toxin-resistant therapeutic stem cells to treat brain tumors Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.Evidence of canonical somatic hypermutation in hairy cell leukemia Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.Targeting malignant B cells with an immunotoxin against ROR1 Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells Immunoconjugates in the management of hairy cell leukemia.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

P2860

Q24635904-B7BBCAD8-10AB-4A18-905E-2C6C0022F128 Q26738984-2A9D325B-9699-4F74-B5FF-9948B04C79F7 Q26796423-BC31D368-601A-42C1-A4C3-B0D6696B1BED Q27013664-BB7652A6-209F-44A0-A65E-88EB37DE3D6F Q27022540-353CF51D-7A6E-47B6-9F95-32E9058E3840 Q27314650-2AAEC5F0-7482-4274-8BBE-47CAD11392A9 Q28553712-02455269-B342-4DD2-8457-B0D921E884D5 Q33410756-17501C2F-48E8-43A2-BCB7-20959BEC231C Q33415933-847210AC-B2C2-4684-A7F7-0B3CC1647C55 Q33604776-E44AB769-A0A2-45CB-91DB-DE42BA108B6F Q33689021-75EBCF29-FC40-4939-B4DA-8CB504F09065 Q33732575-92C20696-B674-41F9-836A-7FC3B226EEAE Q33752982-B63E429E-FDE0-440B-A861-668D6A902108 Q33779122-3686C555-4F5F-4FE3-9916-07DDB6767CC2 Q33840201-37730CF9-4C4F-4CB2-BD6F-22C23EA83036 Q33932779-55CC9F0F-60F8-41A4-A2E0-2284A4C5F8B8 Q34276680-AAD9E834-AD21-4C5D-9C3D-C441C6E723B6 Q34343369-31FF5055-3A10-4C91-9AFE-C91ECC631738 Q34387911-D305D804-B455-4D54-B121-FE5D444AE6AD Q34444939-AB3C1545-1B80-46FC-8C33-0ACE93AD6D49 Q34575951-AC79AB40-24FE-4868-BA0A-1DCF18ACA846 Q34619308-7DC728C4-4FE6-41AD-8FB9-5F37EB5B2C8C Q34804520-B3837C77-492C-4C7A-ADD0-31C357C9AA1B Q34993336-C44330B5-272B-432C-8A5C-B7E630AECF95 Q35001615-08C256DC-A33D-4F1B-90A9-6BDF8C8974F5 Q35023967-73D65464-45B0-4A9E-BFFB-EF0CD8D4CA7B Q35230663-4A2C6F1D-2313-4F72-B6F9-51DBA25A6BDC Q35317540-140EB9C0-5C3E-4A90-907F-364B2425320E Q35446035-CC73652E-A9D8-4261-8549-494FBFE28F23 Q35446333-6EAADD1B-F510-4E21-A3A1-9600CD71ADDB Q35653164-D7DD3B74-A62D-4974-A988-3AA9A97D0412 Q35935802-54191F33-F02F-476F-82C6-DED5E50D025A Q35969887-56902AD9-55C9-40CD-A071-3D66EEEA36A6 Q36058502-206932C4-8B8F-4E45-B54B-6C0FA92B381E Q36073562-5EF51A78-C749-47C6-A290-4AC00D2FFFFD Q36200380-84F85FA4-6D77-4733-BFEF-E094F711BB8E Q36269852-CF56B719-19BE-4644-A356-13122DB341F7 Q36328016-D5B66E54-5D8D-4808-8EFC-CCAD5D72ED1C Q36339717-78DE2877-79BC-457D-BD6D-2A2C070CE049 Q36346628-E04BE674-2783-47DF-B280-FCFEA10D9FF7

P2860

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

http://www.wikidata.org/entity/Q37242280

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trial of recombinant immunotoxin RFB4

@nl

Phase II trial of recombinant ...... ents with hairy cell leukemia.

@en

type

label

Phase II trial of recombinant immunotoxin RFB4

@nl

Phase II trial of recombinant ...... ents with hairy cell leukemia.

@en

prefLabel

Phase II trial of recombinant immunotoxin RFB4

@nl

Phase II trial of recombinant ...... ents with hairy cell leukemia.

@en

P1433

Q37242280-0917F69B-28B0-4587-903F-3CE32C4CDF98

P1476

Q37242280-035436D5-3178-4571-B171-6B6FBBDE9D82

P2093

Q37242280-1988CD3D-286E-4981-8B2E-18F79C7A1458

Q37242280-40014FD6-3450-4247-A306-40ED707C4073

Q37242280-4738B091-4E21-479E-8E8E-3888A608A3CB

Q37242280-7466B7CE-8040-4C84-B021-0CBF40786BC2

Q37242280-995443B8-4118-4456-A51F-5DFD6B14FCA7

Q37242280-B2FE9216-2F3C-4908-A1BC-E54909294EF6

Q37242280-DC508413-4A06-4442-B8A6-CA861B357D61

P2860

Q37242280-034C3DDF-BF38-48DB-A5C6-4CAC60030ADF

Q37242280-18A526E7-A7B4-423C-8488-BC4507AEC449

Q37242280-1D9D4B76-F3B6-46C7-92C7-FAA1EADA8375

Q37242280-5EF5418D-537E-49B8-A6DE-B15B8EF15529

Q37242280-86B26F02-6C8F-4328-8130-08D38EC5E194

Q37242280-8FD17186-F5EA-4BBE-AD8E-8A8AC940BADF

Q37242280-91D36F52-3AFF-450A-BF75-0D134F625B8C

Q37242280-98467D17-E10A-4FCC-80F4-01840B8F4909

Q37242280-B2542A25-B86D-4E24-8B84-46DA0B9DEB6B

Q37242280-B7B59BAF-EFD2-4E0D-AFCD-DDA591334F06

P304

Q37242280-867ADF54-C7EE-41C7-91BA-671A334A75C7

P31

Q37242280-D3FE956C-4B24-4296-AB9C-5E254D9F20D6

P356

Q37242280-41B58D87-F213-4863-B57F-2C778E7DDB01

P407

Q37242280-7ECD8446-97ED-4F83-AB10-CFED42A0760C

P433

Q37242280-D02F70E7-ECE0-4A2D-9ABE-7ECBA966F155

P478

Q37242280-6AC3B0E8-A754-4D70-93AA-A16348D2D5DD

P577

Q37242280-A78C4334-76AF-4F24-8F03-205E90F0E59A

P698

Q37242280-624B8894-29A0-4F2A-9386-1F9F9B1FD34C

P921

Q37242280-1F517051-8EF2-43A7-B722-A988F5AF43AA

Q37242280-4FF90596-F21B-4284-A53E-D1C369A668B6

P932

Q37242280-82C9B571-597B-460D-B952-7F9293EFA9C0

P356

JCO.2008.20.2630

P1433

Journal of Clinical Oncology

P1476

Phase II trial of recombinant ...... ents with hairy cell leukemia.

@en

P2093

David J P Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Inger Margulies

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler-Stevenson

http://www.w3.org/2001/XMLSchema#string

Pierre Noel

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

Wyndham H Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.

Immunotoxin treatment of cancer.

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

Rituximab in relapsed or refractory hairy cell leukemia.

Pentostatin: impact on outcome in hairy cell leukemia.

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia

P304

2983-2990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.2630

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19414673

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2702232

http://www.w3.org/2001/XMLSchema#string